Canaccord Genuity Downgrades Zynerba Pharmaceuticals to Hold, Lowers Price Target to $1.11
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Sumant Kulkarni has downgraded Zynerba Pharmaceuticals from Buy to Hold and lowered the price target from $10 to $1.11.

August 16, 2023 | 9:50 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Zynerba Pharmaceuticals has been downgraded from Buy to Hold by Canaccord Genuity, with a lowered price target of $1.11.
The downgrade from Buy to Hold by Canaccord Genuity indicates a less optimistic outlook for Zynerba Pharmaceuticals. The significant reduction in the price target from $10 to $1.11 suggests that the analyst sees limited upside potential for the stock, which could negatively impact its short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100